A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging

Surgery

Volumn 132, Issue 4, 2002, Pages 589-604

  Averbook, Bruce J ^a   Fu, Pingfu ^a   Rao, J Sunil ^a   Mansour, Edward G ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SKIN ULCER; STATISTICAL ANALYSIS; THICKNESS; TUMOR VOLUME;

EID: 0036775519     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2002.127546     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
3. Balch CM, Buzaid AC, Soong S, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
4. Cox DR. Regression models in life tables (with discussion). J R Stat Soci Series B, 1972;34:187-220.
5. Averbook BJ, Russo LJ, Mansour EG, A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124:746-56.
6. Breiman L, Friedman JA, Olshen R, Stone C. Classification and Regression Tree. New York: Wadsworth; 1984.
7. Gordon L, Olshen RA. Tree-structured survival analysis. Cancer Treat Rep 1985;69:1065-9.
8. Segal M. Regression trees for censored data. Biometrics 1988;44:35-47.
9. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis [comments] J Clin Oncol 1990;8:963-77.
10. Carmelli D, Halpern J, Swan GE, Dame A, McElroy M, GelbAB, et al. 27-year mortality in the western collaborative group study: Construction of risk groups by recursive partitioning. J Clin Epidemiol 1991;44:1341-51.
11. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992;48:411-25.
12. Gelb AB, Shibuya RB, Weiss LM, Medeiros LJ. Stage I renal cell carcinoma: A clinicopathologic study of 82 cases. Am J Surg Pathol 1993;17:275-86.
13. Wager C, Segal M. Tree Structured Survival Analysis Methods and Software. 1996; http://lib.stat.cmu.edu/S.tssa.
14. Carmelli D, Zhang H, Swan GE. Obesity and 33-year follow-up for coronary heart disease and cancer mortality [comments]. Epidemiology 1997;8:378-83.
15. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
16. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Malignant melanoma of the skin (excluding eye). In: American Joint Committee on Cancer Manual for Staging of Cancer. 4th Ed. Philadelphia: J.B. Lippincott; 1992. p. 143-8.
17. Balch CM, Soong, SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
18. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.
19. Morton DL, Wen D, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
20. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R, et al. Intraoperative radio-lymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
21. Reintgen D, Rapaport D, Tanabe KK, Ross M. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. J Fla Med Assoc 1997;84:188-93.
22. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial: Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63.
23. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, et al. Sentinel lymph node biopsy for melanoma: How many radioactive nodes should be removed? Ann Surg Oncol 2001;8:192-7.
24. Dessureault S, Soong S, Ross MI, Thompson JF, Kirkwood JM, Coit DG, et al. Improved staging of node-negative patients with intermediate to thick melanomas > 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001;8:766-70.
25. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.